Literature DB >> 16027042

Humoral autoimmune responses to glutamic acid decarboxylase have similar target epitopes and subclass that show titer-dependent disease association.

Sandra Piquer1, Cristina Belloni, Vito Lampasona, Elena Bazzigaluppi, Marika Vianello, Bruno Giometto, Emanuele Bosi, Gian Franco Bottazzo, Ezio Bonifacio.   

Abstract

Glutamic acid decarboxylase (GAD) is an autoantigen in stiff man syndrome (SMS) and type 1 diabetes (T1DM). Different GAD autoantibody characteristics in these disorders have suggested distinct underlying mechanisms of autoimmunity. Here, it is shown that increased prevalence of autoantibodies to GAD65 amino terminal and GAD67 epitopes and autoantibodies of IgG2, IgG3, or IgG4 subclass in patients with SMS (P < 0.001 vs. T1DM) are secondary to the markedly higher autoantibody titers in SMS patients (P < 0.0001) and that autoantibody epitopes and subclasses were similar when patients were matched for autoantibody titer. Exposure to autoantigen in the disorders is likely to involve similar humoral antigenic determinants, but different B cell regulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16027042     DOI: 10.1016/j.clim.2005.06.009

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  13 in total

Review 1.  Diabetes and epilepsy in children and adolescents.

Authors:  M Loredana Marcovecchio; Marianna Immacolata Petrosino; Francesco Chiarelli
Journal:  Curr Diab Rep       Date:  2015-04       Impact factor: 4.810

2.  Reduced display of conformational epitopes in the N-terminal truncated GAD65 isoform: relevance for people with stiff person syndrome or DQ8/8-positive Type 1 diabetes mellitus.

Authors:  C S Hampe; J R Radtke; A Wester; A Carlsson; E Cedervall; B Jönsson; S A Ivarsson; H Elding Larsson; K Larsson; B Lindberg; J Neiderud; O Rolandsson; Å Lernmark
Journal:  Diabet Med       Date:  2018-12-28       Impact factor: 4.359

Review 3.  Intravenous immunoglobulin therapy in paraneoplastic neurological syndromes.

Authors:  Raymond Voltz
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

4.  The glutamic acid decarboxylase 65 immunoglobulin G subclass profile differs between adult-onset type 1 diabetes and latent autoimmune diabetes in adults (LADA) up to 3 years after clinical onset.

Authors:  M Hillman; C Törn; M Landin-Olsson
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

5.  Characteristics of in-vitro phenotypes of glutamic acid decarboxylase 65 autoantibodies in high-titre individuals.

Authors:  M Chéramy; C S Hampe; J Ludvigsson; R Casas
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

6.  GAD autoantibodies and epitope reactivities persist after diagnosis in latent autoimmune diabetes in adults but do not predict disease progression: UKPDS 77.

Authors:  M Desai; C A Cull; V A Horton; M R Christie; E Bonifacio; V Lampasona; P J Bingley; J C Levy; I R Mackay; P Zimmet; R R Holman; A Clark
Journal:  Diabetologia       Date:  2007-07-27       Impact factor: 10.122

Review 7.  Islet Autoantibodies.

Authors:  Vito Lampasona; Daniela Liberati
Journal:  Curr Diab Rep       Date:  2016-06       Impact factor: 4.810

8.  An analysis of the cross-reactivity of autoantibodies to GAD65 and GAD67 in diabetes.

Authors:  Bindu Jayakrishnan; David E Hoke; Christopher G Langendorf; Ashley M Buckle; Merrill J Rowley
Journal:  PLoS One       Date:  2011-04-08       Impact factor: 3.240

9.  Detection of Antibodies Directed to the N-Terminal Region of GAD Is Dependent on Assay Format and Contributes to Differences in the Specificity of GAD Autoantibody Assays for Type 1 Diabetes.

Authors:  Alistair J K Williams; Vito Lampasona; Michael Schlosser; Patricia W Mueller; David L Pittman; William E Winter; Beena Akolkar; Rebecca Wyatt; Cristina Brigatti; Stephanie Krause; Peter Achenbach
Journal:  Diabetes       Date:  2015-05-13       Impact factor: 9.461

10.  Neuronal surface and glutamic acid decarboxylase autoantibodies in Nonparaneoplastic stiff person syndrome.

Authors:  Thashi Chang; Haris Alexopoulos; Mary McMenamin; Alexander Carvajal-González; Sian K Alexander; Robert Deacon; Ferenc Erdelyi; Gabor Szabó; Szabó Gabor; Bethan Lang; Franz Blaes; Peter Brown; Angela Vincent
Journal:  JAMA Neurol       Date:  2013-09-01       Impact factor: 18.302

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.